Novartis Confirms Nine Tumor Reports in Zolgensma Patients as FDA Opens Safety Probe
- Novartis has received nine tumor reports among patients treated with the SMA gene therapy Zolgensma since its 2019 approval; two show evidence of vector DNA integration.
- The FDA is evaluating whether regulatory action is needed and has extended the review to Itvisma, the intrathecal version, which has no reported tumors.
- The agency says benefits still outweigh risks, and Novartis notes integration risk is already in the label; over 6,000 patients have been treated.
💡 Points Based on public reports
Nine reports across 6,000-plus patients is a low rate, so the issue is causality: two integration cases and a GLI1 signal will decide whether this stays a label footnote. The read-across matters more than Zolgensma itself, because the same vector underpins Itvisma and other AAV programs that rely on the 'rare, already labelled' argument. Patient groups' complaints about disclosure speed add a trust cost.
📰 Source · STAT News ↗ Novartis SMA Zolgensma tumor case reports